What Dalivit Treats: Main Uses and Benefits

Dalivit injectable solution is commonly used for acute systemic support in crisis situations, combining a corticosteroid with components used for supportive purposes. Its main use is to treat conditions involving severe physiological stress, which may lead to states of shock or acute adrenal crisis.

The medicine plays a role in managing symptoms related to systemic imbalance and inflammatory states in these scenarios. For instance, the use of intravenous Hydrocortisone in severe stress states like trauma, major surgery, and intensive care is considered relevant within clinical practice.

The formulation also includes components relevant for addressing energy deficits and supportive purposes. This combination is commonly used to help with supportive relief during acute inflammatory and circulatory states while supporting the management of profound metabolic stress and energy deficits. The overall therapeutic benefit supports general well-being during symptomatic phases, contributing to easing the overall symptom load associated with critical illness.

“The treatment is applied across domains where additional symptomatic support is needed, especially when symptoms create noticeable physiological strain.”

---

Quick Fact: Relief for Systemic Imbalance

The medicine is considered relevant for conditions presenting with acute episodes, such as shock states, severe inflammation, and acute adrenal crisis.

Who can and cannot use Dalivit?

The eligibility for the Dalivit injectable solution is defined by regulatory documents based on its active components, Hydrocortisone and Glutamine, and applies to adults and children over one month of age.

Use is Contraindicated (Must Not Be Used) in Patients with:

• Systemic Fungal Infections: This is an absolute prohibition due to the immunosuppressive effect of the corticosteroid component.
• Severe Organ Dysfunction: Individuals with severe liver disease or severe kidney disease must not use the medicine, as the Glutamine component may worsen these conditions.
• Hereditary Metabolic Conditions: The medicine is contraindicated in patients with hereditary fructose intolerance due to the presence of Fructose-related components.

Eligibility Restrictions and Special Cautions:

• Infants ≤ 1 Month Old: Safety and efficacy are not established in this age group.
• Conditional Use: Patients with pre-existing conditions such as diabetes mellitus, hypertension, osteoporosis, or latent tuberculosis require particular care and close monitoring, as the Hydrocortisone component may exacerbate these conditions.
• Reproductive Status: Use during pregnancy and lactation is generally not recommended and must follow a strict regulatory benefit-risk assessment.

Interaction Scope

Dalivit is a multivitamin preparation whose interaction profile is dominated by the high-dose components, specifically Vitamin A and Vitamin D. Officially documented interactions involve specific medicinal product categories, leading to risks of toxicity or altered vitamin requirements.

Interacting Product Category	Effect on Dalivit Component
Anticonvulsants (e.g., Phenytoin, Barbiturates)	May increase Vitamin D requirements
Retinoids (e.g., Acitretin, Isotretinoin)	Increased risk of hypervitaminosis A (Additive Toxicity)
Thiazide Diuretics	Increased risk of hypercalcemia (Pharmacodynamic Synergism)
Neomycin	Possibly reduced absorption of Vitamin A

Regulatory Constraints

Official regulatory documents enforce specific constraints due to the risk of toxicity:

• Other Supplements: No other preparation containing Vitamin A or Vitamin D should be taken concurrently except under medical supervision. This restriction is mandated to mitigate the Additive Hypervitaminosis Risk inherent in combination with other supplements.
• Population Notes: Special considerations apply to specific populations. The label notes that Vitamin D is secreted in breast milk and may cause hypercalcemia in infants. Furthermore, women who are or may become pregnant are advised against taking Vitamin A supplements due to potential risks.

Official Interaction Structure

The interaction structure is defined by consequences: drugs like Carbamazepine and Primidone are listed as potentially increasing the body’s need for Vitamin D, while Retinoids and Thiazide diuretics increase the risk of serious toxic effects (hypervitaminosis A and hypercalcemia, respectively). The overall profile requires careful accounting for all sources of Vitamins A and D when the product is prescribed.

Dalivit's mechanism of action is defined by the individual roles of its two key components, Vitamin D and Vitamin A.

Vitamin D: Calcium Homeostasis Modulation

Vitamin D (Calciferol) acts as a prohormone. It is metabolized in the liver and kidney into the active form, 1,25( OH)2D3 (Calcitriol), which serves as a ligand for the Vitamin D Receptor (VDR), a nuclear receptor. VDR-ligand binding modulates gene transcription primarily in the intestinal epithelium to stimulate the synthesis of calcium transport proteins. This action promotes the absorption of dietary calcium and phosphate and is a primary driver of systemic calcium homeostasis, leading to the subsequent mineralization of the skeletal matrix.

Vitamin A: Gene Expression and Phototransduction

Vitamin A (Retinol) functions through two main mechanistic pathways. In the visual system, Retinal is required to form rhodopsin, a light-sensitive pigment integral to the phototransduction cascade within the rod cells of the retina. Systemically, Retinol is converted to Retinoic Acid, which acts as a signaling molecule. Retinoic Acid binds to intracellular Retinoic Acid Receptors (RARs) and Retinoid X Receptors (RXRs). These receptor-ligand complexes operate as transcription factors to modulate the expression of genes involved in cellular differentiation and proliferation.

How Dalivit is Used

The use of Dalivit Injectable Solution is governed by strict, label-based administration and dosing guidelines, reflecting its application as a short-term intervention in acute physiological crisis situations.

Official Routes of Administration

Dalivit is approved for parenteral administration only, which is required to achieve rapid systemic stabilization. The official routes include:

• Intravenous (IV) Injection or IV Infusion (preferred for initial emergency use).
• Intramuscular (IM) Injection (an approved alternative route).

Standard Dosing and Frequency

Dosing is based on the severity of the patient's condition and the official regimen for the primary component, Hydrocortisone. Dosage details are based on established regulatory standards.

Dosing Parameter	Official Label Regimen (Hydrocortisone equivalent)
Initial Dose Range (Adults)	100 mg to 500 mg
Maintenance Frequency	May be repeated at intervals of 2, 4, or 6 hours based on clinical need.

Administration Requirements and Duration

Due to its form as a lyophilized powder, the solution requires reconstitution with sterile water before use. For IV injection, administration must be timed carefully, lasting between 30 seconds to 10 minutes depending on the total dose.

Treatment with the injectable solution is intended for short-term, acute intervention and should generally not be continued beyond 48 to 72 hours once the crisis has stabilized. Following this period, the official protocol mandates transitioning the patient to an alternative, such as an oral corticosteroid preparation.

Population-Specific Guidance: For the pediatric population, the minimum dose should generally not be less than 25 mg daily, while older adults require close clinical supervision.

Dalivit: Recent Clinical Evidence

Clinical research regarding multivitamin supplementation, such as that provided by Dalivit, primarily focuses on the efficacy of its constituent vitamins in preventing or treating deficiencies, particularly in high-risk groups like infants and young children. The product typically contains a combination of Vitamin A, Vitamin D, Thiamine (B1), Riboflavin (B2), Pyridoxine (B6), Vitamin C, and Nicotinamide.

Evaluation in Deficiency Prevention

Studies have assessed the impact of multivitamin supplementation in populations vulnerable to nutritional gaps, including those with restricted diets, malabsorption issues, or high metabolic demands. Evidence supports the use of specific vitamins within the product to maintain adequate levels essential for growth and development.

• Vitamin D: Numerous trials emphasize the role of Vitamin D supplementation in infants to support bone health and prevent rickets. Research indicates that low intake is prevalent in many populations, necessitating careful monitoring and supplementation.
• Vitamin C: Research has examined Vitamin C's role in supporting immune function and collagen formation, though trials typically evaluate its use in deficiency states like scurvy.
• B Vitamins: Studies focus on the role of B-complex vitamins (B1, B2, B6, Nicotinamide) in energy metabolism and nervous system function. Deficiencies are often linked to specific dietary restrictions or underlying medical conditions.

Limitations of Evidence

The most conclusive data relates to preventing specific single-vitamin deficiencies. For individuals already consuming a balanced diet, evidence of a measurable health benefit from routine multivitamin supplementation remains limited. The product's overall clinical utility is centered on its established function as a nutritional support during periods of deficiency risk.

Key Studies & References

1. Vitamins for children (NHS Guidance)

Common questions about Dalivit (FAQ)

Q: Why do people say Dalivit is good for babies?

A: Official product information, such as the Summary of Product Characteristics, states that Dalivit Oral Drops are specifically indicated for the prevention of vitamin deficiency states. They are also used as an aid to maintain normal health and growth during the early years of infancy and childhood (from 6 weeks of age). This regulatory indication is the basis for its association with use in babies.

Q: Is Dalivit safe to take long-term?

A: Regulatory documents caution against chronic excessive consumption of the product, as this can lead to a condition called hypervitaminosis (toxicity from too much vitamin intake), particularly from the fat-soluble Vitamins A and D. For this reason, official guidance emphasizes the regulatory constraint that the stated daily dose is not to be exceeded over long periods.

Q: What does Dalivit taste like?

A: Official regulatory descriptions focus on the physical appearance of the medicine. They note that the Oral Drops formulation is a yellowish-orange colored liquid that is slightly viscous. Specific details about the product's flavor or taste are not typically included in the official regulatory documentation.

Q: Is Dalivit the same as Abidec?

A: Regulatory guidance and official comparative information, such as that issued by public health services, note that while both are multivitamin drops for children, they are not identical. The documents indicate that Dalivit Drops and Abidec Drops have differences in their ingredients, specifically the content of certain vitamins (like Vitamin A) and other non-active components (excipients).

Q: Can I take Dalivit if I have a food allergy?

A: The medicine is contraindicated, which means its use is prohibited according to regulatory labels, if there is a known hypersensitivity or allergy to any of its active substances or inactive components (excipients). Official warnings also specifically note that an excipient used in the formulation, Sodium methylhydroxybenzoate (E219), may cause allergic reactions.

Q: Is Dalivit safe for elderly patients?

A: Official product information directs the use of the drops for a wide population, including older children, adults, and the elderly. For the elderly population, official information notes that a specific, individualized dosage is typically directed by a physician.

Q: How long is the shelf life of Dalivit once opened?

A: The official instructions for the stability of the product after opening advise that the Dalivit Vitamin D3 Drops are safe for use for a period of up to 12 months after the container is first opened. The official instructions set the in-use stability period at this time limit.

Q: Can Dalivit make me feel dizzy?

A: Dizziness is not listed as an undesirable effect in the product's Summary of Product Characteristics (SmPC). However, official warnings regarding excessive use note that symptoms of Vitamin D overdosage can include dizziness, which is a potential risk noted when the stated dosage is exceeded.

Q: Do I need to refrigerate Dalivit?

A: Official storage instructions set the required conditions for the drops to be stored in a dry place below 25 C and protected from light. There is no instruction within the regulatory documents that requires the product to be refrigerated.

Q: Can Dalivit affect blood tests?

A: Official information regarding symptoms of overdosage suggests that excessive consumption can lead to raised plasma and urine calcium and phosphate concentrations. This indicates that the medicine has the potential to affect these specific biochemical parameters which are measured in some blood tests.

Q: Is Dalivit officially recommended for use in the winter?

A: While there is no product-specific recommendation, public health guidance in many regions often emphasizes the role of Vitamin D supplementation for certain populations, particularly during cooler months or periods of low sun exposure. Vitamin D is a key component of Dalivit.

Official Storage and Disposal Requirements

Regulatory documents define specific conditions for the storage, protection, and disposal of Dalivit products.

Requirement	Official Instructions
Temperature	Softgels: Store at 20 C - 25 C (USP Controlled Room Temperature). Drops: Store below 30 C or 25 C, depending on the formulation.
Protection	Protect the medicine from both light and moisture. Softgels must be dispensed in a tight, light-resistant container.
In-Use Stability	Use Dalivit Vitamin D3 Drops within 12 months after first opening. Do not use any product after the printed expiry date.
Child Safety	KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN. Softgels must be dispensed with a child-resistant closure.
Disposal	Dispose of any unused or expired product and waste material strictly according to local pharmaceutical or environmental requirements.